Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices 1107 

6001 Executive Blvd., Rockville, MD 20892, 

(240) 936–6720, emma.perez-costas@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants, National Institutes of Health, HHS) 

Dated: January 4, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00248 Filed 1–8–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Minority Health 

and Health Disparities; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Minority Health and Health Disparities 

Special Emphasis Panel; NIMHD Support for 

Conferences and Scientific Meetings (R13). 

Date: February 13, 2024. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

NIMHD DEM II, Suite 800, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Jingsheng Tuo, Ph.D., 

Scientific Review Officer, Office of 

Extramural Research Administration, 

National Institute on Minority Health and 

Health Disparities, National Institutes of 

Health, 6707 Democracy Blvd., Suite 800, 

Bethesda, MD 20892, (301) 451–5953, 

jingsheng.tuo@nih.gov. 

Dated: January 4, 2024. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00211 Filed 1–8–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID SPF Macaque 

Breeding Colonies. 

Date: February 7, 2024. 

Time: 8:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G53, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Konrad Krzewski, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G53, Rockville, MD 

20852, 240–747–7526, konrad.krzewski@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 3, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00201 Filed 1–8–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Development and 

Commercialization of Thermally 

Responsive T Cell Therapies for the 

Treatment of HPV-Positive Cancer(s) 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this Notice to Port 

Therapeutics, Inc. (‘‘Port’’). Port 

incorporated in Delaware and is 

presently headquartered in Los Angeles, 

California. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before January 24, 2024 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Andrew Burke, Ph.D., 

Senior Technology Transfer Manager, 

NCI Technology Transfer Center, 

Telephone: (240) 276–5484; Email: 

andy.burke@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

1. United States Provisional Patent 

Application No. 62/004,335 filed May 29, 

2014, entitled ‘‘Anti-Human Papillomavirus 

16 E7 T Cell Receptors’’ [HHS Reference No. 

E–176–2014–0–US–01]; 

2. PCT Patent Application No. PCT/ 

US2015/033129 filed May 29, 2015, entitled 

‘‘Anti-Human Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–PCT–02]; 

3. Australian Patent No. 2015266818 

issued January 16, 2020, entitled ‘‘AntiHuman Papillomavirus 16 E7 T Cell 

Receptors’’ [HHS Reference No. E–176–2014– 

0–AU–03]; 

4. Brazilian Patent Application No. 

BR112016027805–4 effective filing date of 

May 29, 2015, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ [HHS 

Reference No. E–176–2014–0–BR–04]; 

5. Canadian Patent Application No. 

2,950,192 effective filing date of May 29, 

2015, entitled ‘‘Anti-Human Papillomavirus 

16 E7 T Cell Receptors’’ [HHS Reference No. 

E–176–2014–0–CA–05]; 

6. Chinese Patent No. ZL201580031789.X 

issued May 4, 2021, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ [HHS 

Reference No. E–176–2014–0–CN–06]; 

7. European Patent No. 3149031 issued 

December 18, 2019, entitled ‘‘Anti-Human 

Papillomavirus 16 E7 T Cell Receptors’’ [HHS 

Reference No. E–176–2014–0–EP–07]; 

a. Validated in: AL, AT, BE, BG, CH, CY, 

CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, 

IE, IS, IT, LT, LU, LV, MK, MT, NL, NO, PL, 

PT, RO, SE, SI, SK, SM and TR. 

8. Israeli Patent No. 248797 issued 

September 1, 2021, entitled ‘‘Anti-Human 


khammond on DSKJM1Z7X2PROD with NOTICES